The Newsletter
The Principals
Custom Research
Contact Us

Online Report Subscribers, Click Here

Pricing and Ordering Information


U.S. Ophthalmic Surgical Systems Market
Report #A560
- April 2014
84 Pages – 13 Exhibits – 6 Company Profiles

In the United States (U.S.), serious ophthalmic disease affects more than 35 million. This number is expected to significantly increase due to the aging of the population and disorders such as diabetes that may result in progressive vision loss. Alarmingly, the number of patients with cataracts is expected to increase significantly over the next decade, contributing a substantial increase in the number of cataract surgeries.

The development of new, minimally invasive energy-based (laser/phacoemulsification or “phaco”) technologies is providing safe and effective, medically necessary, vision-saving treatment to millions of patients, particularly those with cataracts who also seek vision correction surgery. Meanwhile, non-medically necessary, high-cost refractive surgery, such as laser in situ keratomileusis (LASIK) vision correction, continues to increase despite several setbacks.

Overall, more than an estimated 5.5 million directed-energy based (laser/phaco) ophthalmic procedures, including cataract laser surgery, diabetic retinopathy laser surgery, glaucoma/laser trabeculoplasty and laser-based vision correction surgery, were estimated to have been performed in the U.S. in 2013. The advancement of safer and more cost-effective laser-based technologies, such as femtosecond laser cataract surgery and other technological improvements, are expected to improve patient outcomes and drive ophthalmic surgical procedures and market growth over the next half-decade.

For the purposes of this report, the U.S. market for ophthalmic surgical systems includes sales derived from laser and phaco systems for vision correction and the minimally invasive treatment of cataracts, glaucoma, retinal, and other ophthalmic disorders. In addition to ophthalmic surgical systems sales, the market forecast includes revenues derived from surgical accessories/instruments and disposables utilized in minimally invasive directed energy-based ophthalmic surgery. In 2013, the U.S. ophthalmic surgical systems market was valued at approximately $1,695.8 million. Over the forecast period covered by this report, total sales in this market are expected to increase at a compound annual rate of 5.9%, reaching an estimated $2,256.4 million in the year 2018.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. ophthalmic surgical systems market. Covered topics in this report include an overview of common ophthalmic diseases/disorders and therapies; U.S. procedure volumes; laser/phaco/energy-based surgical systems, next-generation laser-based systems and emerging technologies; and company profiles.

Ordering Information


Report# Publication
List Price

U.S. Ophthalmic Surgical Systems Market


April 2014


Order Online:
Single User only (Please call for corporate subscription pricing)
PDF Only

Print versions of Reports are available upon request for an additional fee.


Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.





i.         Clinical Overview

a.        Age-Related Macular Degeneration

b.        Cataracts

c.      Diabetic Retinopathy

d.      Glaucoma

e.       Refractive Errors

ii....... Market

iii.         Methodology



1.       U.S. ophthalmic surgical systems market

1.1       Clinical Overview

1.1.1    Age-Related Macular Degeneration

1.1.2    Cataracts

1.1.3    Diabetic Retinopathy

1.1.4    Glaucoma

1.1.5    Refractive Errors

1.2       Ophthalmic Procedures

1.2.1    Age-Related Macular Degeneration Anti-Angiogenic Therapy Verteporfin Photodynamic

            Therapy Transpupillary Thermotherapy Retinal Photocoagulation

1.2.2    Cataract Surgery Capsulotomy Procedure Volumes Forecast

1.2.3    Diabetic Retinopathy Laser Surgery Procedure Volumes Forecast

1.2.4    Glaucoma—Laser Trabeculoplasty Procedure Volumes Forecast

1.2.5    Refractive Surgery Laser-Based Vision Correction Photorefractive Keratectomy Laser In Situ Keratomileusis Laser Epithelial Keratomileusis Photoablative Inlay Laser In Situ

            Keratomileusis Procedure Volumes Forecast

1.3       Market Analysis

1.3.1    Market Forecast

1.4       Competitive Analysis

1.4.1    Market Share


Exhibit 1-1:.. 2013, Estimated U.S. Prevalence of Selected  Ophthalmic Conditions

Exhibit 1-2:.. Laser Therapy for Age-Related Macular Degeneration, U.S. Procedure Volumes Forecast, 2011-2018

Exhibit 1-3:.. Cataract Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)

Exhibit 1-4:.. Diabetic Retinopathy Laser Surgery, U.S. Procedure  Volumes Forecast, 2011-2018 (in Thousands)

Exhibit 1-5:.. Glaucoma Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)

Exhibit 1-6:.. Refractive Laser Surgery, U.S. Procedure Volumes Forecast, 2011-2018 (in Thousands)

Exhibit 1-7:.. Selected Market Drivers and Limiters

Exhibit 1-8:.. U.S. Ophthalmic Surgical Systems, Market Forecast, 2013-2018

Exhibit 1-9:.. 2013, U.S. Ophthalmic Surgical Systems Market,  Estimated Percentage of Sales, by Application

Exhibit 1-10:... 2013, Leading Competitors in the U.S. Ophthalmic Surgical Systems Market and Applications for Leading Products

Exhibit 1-11:... 2013, U.S. Ophthalmic Surgical Systems Market,  Share by Supplier


2.  company profiles

2.1       Abbott Laboratories

2.1.1    Background

2.1.2    Abbott Medical Optics Division

2.1.3    Acquisitions

2.1.4    Surgical Systems

2.1.5    Medical Optics Revenues

2.1.6    Selected Financials

2.2       Carl Zeiss Meditec AG

2.2.1    Background

2.2.2    Carl Zeiss Ophthalmology Business

2.2.3    Acquisitions

2.2.4    Surgical Systems

2.2.5    Ophthalmology Segment Revenues

2.2.6    Selected Financials

2.3       IRIDEX Corporation

2.3.1    Background

2.3.2    Acquisitions/Divestitures

2.3.3    Surgical Systems

2.3.4    Selected Financials

2.4       Lumenis Ltd.

2.4.1    Background

2.4.2    Ophthalmic Division

2.4.3    Surgical Systems

2.4.4    Ophthalmic Division Revenues

2.4.5    Selected Financials

2.5       Novartis

2.5.1    Background

2.5.2    Alcon Division

2.5.3    Acquisitions

2.5.4    Surgical Systems

2.5.5    Alcon Division Revenues

2.5.6    Selected Financials

2.6       Valeant Pharmaceuticals

2.6.1    Background

2.6.2    Bausch and Lomb

2.6.3    Acquisitions

2.6.4    Surgical Systems

2.6.5    Bausch + Lomb Revenues

2.6.6    Selected Financials



To order reports or obtain information about special pre-publication offers from within the U.S., contact You can also call 1.908.748.1221 (or toll-free within the U.S. at 1.888.670.8900) or fax 1.646.666.9878.


The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home